GHRP-2 Acetate | 10 vials

GHRP-2 (Growth Hormone-Releasing Peptide-2) , also known by its generic name Pralmorelin, is a synthetic hexapeptide that acts as a potent growth hormone secretagogue . It was developed as part of research into small peptides that stimulate growth hormone (GH) release and is an analogue of ghrelin, activating the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor .

Key Specifications:

• CAS Number: 158861-67-7

• Synonyms: Pralmorelin, KP-102, GPA 748, WAY-GPA-748

• Molecular Formula: C₄₅H₅₅N₉O₆ (approx., based on structure)

• Molecular Weight: Approximately 817.43 g/mol

• Purity: ≥95-98% (research grade)

• Appearance: Lyophilized powder

• Storage: Store at -20°C; protect from light and moisture

Mechanism of Action:

GHRP-2 functions as a full agonist at the growth hormone secretagogue receptor 1 alpha (GHS-R1α) , the same receptor targeted by the natural hormone ghrelin . Key features include:

• GHS-R1α activation: Binds to and activates the ghrelin receptor in the pituitary gland and hypothalamus

• Synergistic GH release: Acts synergistically with growth hormone-releasing hormone (GHRH) to stimulate GH secretion

• cAMP pathway involvement: Increases intracellular cAMP concentrations in somatotrophs, similar to GHRH in some species

• Less sensitive to somatostatin: GH-releasing activity is less suppressed by endogenous somatostatin compared to GHRH

• Hypothalamic action: Requires the median eminence (endogenous GHRH) to exert full GH-stimulating activity

Key Research Applications:

Clinical Status:

Pralmorelin (GHRP-2) is approved in Japan (since 2004) as a diagnostic agent for hypothalamo-pituitary function and growth hormone deficiency . It has also been investigated for the treatment of short stature (pituitary dwarfism), with development reaching Phase II trials .

Important Notice:

FOR RESEARCH USE ONLY. NOT FOR HUMAN USE, THERAPEUTIC, OR DIAGNOSTIC APPLICATIONS outside approved clinical settings.